Limited Competition RFA for the IARC Monographs for the Evaluation of Carcinogenic Risks to Humans

Ron Johnson, PhD
Program Director
Division of Cancer Biology
Purpose

• Limited competition RFA for the Monograph program at the International Agency for Research on Cancer (IARC)
• IARC Monographs - critical scientific evaluations of carcinogenic hazards to humans
• NCI support since 1982 via an U01 award
• IARC award not previously associated with a funding announcement but is now required
• This RFA will enable submission of a renewal application
IARC Monograph Process

- Types of agents considered
  - Chemicals and chemical mixtures
  - Physical and biological agents
  - Occupational exposures and lifestyle factors

- Prioritized by Advisory Group

- Criteria
  - Extent of human exposure
  - Suspicion of carcinogenicity
  - Public health relevance or public concern
  - New or unpublished studies
IARC Monograph Process

• Working Group reviews literature comprehensively
  - Exposure data
  - Cancer epidemiology studies
  - Cancer bioassays in animals
  - Mechanistic data

• Determination based on weight of evidence
• Three Working Groups per year (NCI funds two)
• Volumes freely available as PDFs
Agents Evaluated or Planned

- High concern
  - Shift work, Radiofrequency EMFs, Motor vehicle exhaust
- Global/Low-Middle Income Countries
  - Indoor combustion/cooking, *Schistosoma haematobium*, Areca nut, Chinese-style salted fish
- New & high priority for 2015-2019
  - Bisphenol A, Aspartame, Indium tin oxide, Nicotine/e-cigarettes
IARC Monograph Program

- Authoritative- used by health agencies and institutions world wide
- Well respected- high scientific rigor, independence, and transparency
- Relevant- considers agents of current wide exposure or of high public concern
- Global- evaluates agents of international concern
- Over 900 agents evaluated by 109 Working Groups
Portfolio Analysis

- Unique NIH award
- US carcinogen identification programs
  - Report on Carcinogens (NTP, NIEHS)
  - Integrated Risk Information System (EPA)
- IARC contrasts
  - Broader number and type of agents evaluated
  - Agents of global concern, especially LMICs
  - Frequently the first to evaluate an agent
- IARC complements
  - Involves US agencies (EPA, NIH, CDC) in evaluations and exchange of information
FOA Justification

• **RFA**
  - Limited competition- uniquely positioned institution
  - Review by NCI special emphasis panel

• **U01 (NCI interaction)**
  - Recommend agents for evaluation
  - Identify resource individuals in US
  - Attend or participate in Working Group meetings
Requested Set Aside

- $859,000 TC/year for 5 years
- $4,295,000 total
- Based on current award
- Allocation
  - IARC personnel 80%
  - Convening Working Groups 20%
## IARC vs Report on Carcinogens

<table>
<thead>
<tr>
<th>IARC</th>
<th># Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk to Humans</td>
<td></td>
</tr>
<tr>
<td>Carcinogenic</td>
<td>113</td>
</tr>
<tr>
<td>Probably carcinogenic</td>
<td>66</td>
</tr>
<tr>
<td>Possibly carcinogenic</td>
<td>285</td>
</tr>
<tr>
<td>Not classifiable</td>
<td>505</td>
</tr>
<tr>
<td>Probably not carcinogenic</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Report on Carcinogens</th>
<th># Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinogeniciality</td>
<td></td>
</tr>
<tr>
<td>Known</td>
<td>54</td>
</tr>
<tr>
<td>Reasonably suspected</td>
<td>186</td>
</tr>
</tbody>
</table>